New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers

NCT ID NCT07129252

Recruiting now Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times

Summary

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 participants will be enrolled to see if the drug is safe and can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Crinetics Study Site
RECRUITING

Phoenix, Arizona, 85054, United States
Crinetics Study Site
RECRUITING

Duarte, California, 91010, United States
Crinetics Study Site
RECRUITING

Newport Beach, California, 92663, United States
Crinetics Study Site
RECRUITING

Orange, California, 92868, United States
Crinetics Study Site
RECRUITING

San Francisco, California, 60637, United States
Crinetics Study Site
RECRUITING

Denver, Colorado, 80218, United States
Crinetics Study Site
RECRUITING

New Haven, Connecticut, 48201, United States
Crinetics Study Site
RECRUITING

Atlanta, Georgia, 30322, United States
Crinetics Study Site
RECRUITING

Lexington, Kentucky, 40536, United States
Crinetics Study Site
RECRUITING

Metairie, Louisiana, 70006, United States
Crinetics Study Site
RECRUITING

Detroit, Michigan, 48201, United States
Crinetics Study Site
RECRUITING

Grand Rapids, Michigan, 49503, United States
Crinetics Study Site
RECRUITING

Rochester, Minnesota, 53905, United States
Crinetics Study Site
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Crinetics Study Site
RECRUITING

Austin, Texas, 78758, United States
Crinetics Study Site
RECRUITING

Houston, Texas, 70030, United States
Crinetics Study Site
RECRUITING

Irving, Texas, 75039, United States
Crinetics Study Site
RECRUITING

Salt Lake City, Utah, 84112, United States
Crinetics Study Site
RECRUITING

Charlottesville, Virginia, 22908, United States
Crinetics Study Site
RECRUITING

Fairfax, Virginia, 22031, United States
Crinetics Study Site
RECRUITING

Barcelona, 08023, Spain
Crinetics Study Site
RECRUITING

Barcelona, 08035, Spain
Crinetics Study Site
RECRUITING

Madrid, 28040, Spain
Crinetics Study Site
RECRUITING

Madrid, 28041, Spain

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CRN09682 (a drug given intravenously that targets somatostatin receptor type 2 on tumor cells)

What this could lead to

If successful, this could lead to a new treatment option for people with certain neuroendocrine and other solid tumors that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with only 150 participants, so the drug may not prove effective or safe in larger groups. Side effects, including severe ones, are possible and being studied.

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE NEOPLASM NEUROENDOCRINE NEOPLASM NEUROENDOCRINE TUMORS SST2-POSITIVE NEUROENDOCRINE NEOPLASMS